|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001807,
umls-concept:C0005456,
umls-concept:C0017262,
umls-concept:C0053438,
umls-concept:C0185117,
umls-concept:C0205210,
umls-concept:C0245382,
umls-concept:C0252527,
umls-concept:C0278996,
umls-concept:C0441889,
umls-concept:C0442805,
umls-concept:C0547047,
umls-concept:C2911684
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-1-5
|
|
pubmed:abstractText |
The aim of this study was to investigate whether an increase in malignancy level is accompanied by significant modifications of the expression of galectin-1, galectin-3, and Thomsen-Friedenreich antigen (T antigen) as well as the expression of binding sites for these three markers in head and neck squamous cell carcinomas (HNSCCs).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Tumor-Associated...,
http://linkedlifedata.com/resource/pubmed/chemical/Galectin 1,
http://linkedlifedata.com/resource/pubmed/chemical/Galectin 3,
http://linkedlifedata.com/resource/pubmed/chemical/Hemagglutinins,
http://linkedlifedata.com/resource/pubmed/chemical/Thomsen-Friedenreich antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BisschopPP,
pubmed-author:BurchertMM,
pubmed-author:ChoufaniGG,
pubmed-author:DanguyAA,
pubmed-author:GabiusH JHJ,
pubmed-author:HassidSS,
pubmed-author:KissRR,
pubmed-author:LouryanSS,
pubmed-author:MarchantHH,
pubmed-author:NagyNN,
pubmed-author:SalmonII,
pubmed-author:SaussezSS
|
|
pubmed:copyrightInfo |
Copyright 1999 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2353-63
|
|
pubmed:dateRevised |
2007-12-5
|
|
pubmed:meshHeading |
pubmed-meshheading:10590378-Adjuvants, Immunologic,
pubmed-meshheading:10590378-Adult,
pubmed-meshheading:10590378-Aged,
pubmed-meshheading:10590378-Antigens, Differentiation,
pubmed-meshheading:10590378-Antigens, Tumor-Associated, Carbohydrate,
pubmed-meshheading:10590378-Binding Sites,
pubmed-meshheading:10590378-Carcinoma, Squamous Cell,
pubmed-meshheading:10590378-Female,
pubmed-meshheading:10590378-Galectin 1,
pubmed-meshheading:10590378-Galectin 3,
pubmed-meshheading:10590378-Head and Neck Neoplasms,
pubmed-meshheading:10590378-Hemagglutinins,
pubmed-meshheading:10590378-Humans,
pubmed-meshheading:10590378-Immunohistochemistry,
pubmed-meshheading:10590378-Male,
pubmed-meshheading:10590378-Middle Aged,
pubmed-meshheading:10590378-Neoplasm Staging,
pubmed-meshheading:10590378-Prognosis,
pubmed-meshheading:10590378-Tumor Markers, Biological
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.
|
|
pubmed:affiliation |
Department of Otolaryngology and Head and Neck Surgery, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
